MELANOMA STAGING (TNM SYSTEM) AND PROGNOSTIC FACTORS

Bhavya Batra; Nidhi Pal Singh; Aman Sadaqat; Palak Tomar

Authors

Bhavya Batra
Nidhi Pal Singh
Aman Sadaqat
Palak Tomar

Keywords:

Melanoma, cutaneous melanoma, staging system, American Joint Committee on Cancer (AJCC), TNM classification

Abstract

The process of figuring out how far a cancer has spread and where it is in the body is known as cancer staging. In addition to offering the most precise prognostic estimate, a comprehensive staging is essential since the tumor's stage affects a number of critical decisions, including therapy selection and follow-up tactics. The American Joint Committee on Cancer (AJCC) published the eighth version of the TNM classification in 2017, which serves as the foundation for the current melanoma staging system. There are five stages (0–IV) in both the clinical and pathological staging. The Breslow thickness, the pathological presence or absence of ulceration in the primary tumor, the number and presence of tumor-involved regional lymph nodes, the presence or absence of in-transit, satellite, and/or microsatellite metastases, and the presence of distant metastases are some of the factors that determine the stage of a melanoma. An appropriate medical workup in accordance with the stage and physical examination should be carried out after a melanoma diagnosis. In order to identify a possible recurrence or a second primary melanoma, ongoing patient monitoring is essential and should last a lifetime. Different follow-up plans have been proposed, but there is currently no widely accepted follow-up strategy program. With the rising usage of innovative current medicines (immunotherapies and targeted therapies), future prospective studies are required to assess various follow-up methods based on the chosen therapy.

References

1. Gershenwald, J. E., Scolyer, R. A., Hess, K. R., Sondak, V. K., Long, G. V., Ross, M. I., Lazar, A. J., Faries, M. B., Kirkwood, J. M., McArthur, G. A., Haydu, L. E., Eggermont, A. M. M., Flaherty, K. T., Balch, C. M., Thompson, J. F., & for members of the American Joint Committee on Cancer Melanoma Expert Panel and the International Melanoma Database and Discovery Platform (2017). Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA: a cancer journal for clinicians, 67(6), 472–492. https://doi.org/10.3322/caac.21409

2. Keung, E. Z., & Gershenwald, J. E. (2018). The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care. Expert review of anticancer therapy, 18(8), 775–784. https://doi.org/10.1080/14737140.2018.1489246

3. Hu, D., Liu, Z., Chen, S., Huang, Y., Zeng, W., Wei, W., Zhang, C., Zhou, L., Chen, D., Wu, Y., & Guo, L. (2022). Assessment of the Novel, Practical, and Prognosis-Relevant TNM Staging System for Stage I-III Cutaneous Melanoma. Frontiers in oncology, 12, 738298. https://doi.org/10.3389/fonc.2022.738298

4. Yang, C. Q., Wang, H., Liu, Z., Hueman, M. T., Bhaskaran, A., Henson, D. E., Sheng, L., & Chen, D. (2021). Integrating additional factors into the TNM staging for cutaneous melanoma by machine learning. PloS one, 16(9), e0257949. https://doi.org/10.1371/journal.pone.0257949

5. Balch, C. M., Gershenwald, J. E., Soong, S. J., Thompson, J. F., Atkins, M. B., Byrd, D. R., Buzaid, A. C., Cochran, A. J., Coit, D. G., Ding, S., Eggermont, A. M., Flaherty, K. T., Gimotty, P. A., Kirkwood, J. M., McMasters, K. M., Mihm, M. C., Jr, Morton, D. L., Ross, M. I., Sober, A. J., & Sondak, V. K. (2009). Final version of 2009 AJCC melanoma staging and classification. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27(36), 6199–6206. https://doi.org/10.1200/JCO.2009.23.4799

6. Michielin, O., van Akkooi, A. C. J., Ascierto, P. A., Dummer, R., Keilholz, U., & ESMO Guidelines Committee. Electronic address: [email protected] (2019). Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Annals of oncology : official journal of the European Society for Medical Oncology, 30(12), 1884–1901. https://doi.org/10.1093/annonc/mdz411

7. Balch, C. M., Soong, S. J., Gershenwald, J. E., Thompson, J. F., Reintgen, D. S., Cascinelli, N., Urist, M., McMasters, K. M., Ross, M. I., Kirkwood, J. M., Atkins, M. B., Thompson, J. A., Coit, D. G., Byrd, D., Desmond, R., Zhang, Y., Liu, P. Y., Lyman, G. H., & Morabito, A. (2001). Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 19(16), 3622–3634. https://doi.org/10.1200/JCO.2001.19.16.3622

8. Morton, D. L., Thompson, J. F., Cochran, A. J., Mozzillo, N., Nieweg, O. E., Roses, D. F., Hoekstra, H. J., Karakousis, C. P., Puleo, C. A., Coventry, B. J., Kashani-Sabet, M., Smithers, B. M., Paul, E., Kraybill, W. G., McKinnon, J. G., Wang, H. J., Elashoff, R., Faries, M. B., & MSLT Group (2014). Final trial report of sentinel-node biopsy versus nodal observation in melanoma. The New England journal of medicine, 370(7), 599–609. https://doi.org/10.1056/NEJMoa1310460

9. Hall, B. J., Schmidt, R. L., Sharma, R. R., & Layfield, L. J. (2013). Fine-needle aspiration cytology for the diagnosis of metastatic melanoma: systematic review and meta-analysis. American journal of clinical pathology, 140(5), 635–642. https://doi.org/10.1309/AJCPWSDDHLLW40WI